A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Completed · Phase 1

Conditions studied: Non-alcoholic Steatohepatitis, Hepatic Impairment

In brief

The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.

Key facts

Study ID

NCT06052566

Run by

Merck Sharp & Dohme LLC

People needed

22

Starts

2023-11-21

Expected to finish

2024-12-05

Last updated by the study team

2025-10-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A participant assigned female at birth is eligible to participate if not pregnant or breastfeeding, is not a participant of childbearing potential (POCBP), or is a POCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 35 days after the last dose of study intervention.
• For participants with moderate or severe hepatic impairment: Have a diagnosis of chronic (>6 months), stable, hepatic impairment with features of cirrhosis due to any etiology (stability of hepatic disease should correspond to no acute episodes of illness within the previous 2 months due to deterioration in hepatic function).

You may not qualify if…

• History of cancer (malignancy).
• Had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
• Participants with moderate or severe hepatic impairment who are positive for human immunodeficiency virus (HIV)-1 or HIV-2 at the prestudy (screening) visit.
• Participants with moderate or severe hepatic impairment who received antiviral and/or immune modulating therapy for hepatitis B virus (HBV) or hepatitis C virus (HCV) within 90 days prior to study start.
• Healthy participants who are unable to refrain from or anticipate the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study (including washout intervals between treatment periods), until the poststudy visit.

Where it is running

• Clinical Pharmacology of Miami ( Site 0005) — Miami, Florida, United States
• Advanced Pharma CR, LLC ( Site 0001) — Miami, Florida, United States
• Genesis Clinical Research, LLC ( Site 0006) — Tampa, Florida, United States
• American Research Corporation ( Site 0002) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.